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Abstract: The in vitro synthesis of correctly folded functional proteins remains challenging. Chemokines, which
consist of only 70–100 amino acids, are accessible through solid­phase synthesis and easily fold into a thermally
stable tertiary structure. From the time of their discovery in the late 1980s chemokines could therefore be
synthesized using biochemical and chemical protocols for structure­function analyses and for exploring the
chemokine system in vitro and in vivo. In this short overview aimed at a chemistry­oriented readership we will
introduce chemokines in general, and then discuss their structure, their isolation from biological materials, as
well as the different methods to produce chemokines in the laboratory and finally we will present some examples
of their functions in vivo.
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Introduction
Cytokines are secreted proteins, which
activate and mediate communication be-
tween immune cells, regulate hemato-
poiesis, and immune responses during
inflammation. Chemotactic cytokines, a
large subfamily with approx. 50 members,
are functionally characterized by their
ability to stimulate cell migration through
cognate G-protein coupled receptors
(GPCRs).
[1]
From an evolutionary point of
view, the chemokine system is conserved
from jawed vertebrates to humans. Some
chemokines are highly conserved and can
stimulate cells in fish as well as in mam-
mals. Chemokines are small proteins of
8–12 kDa, which share four cysteines
forming two characteristic disulfide bonds
that are critical for their conserved struc-
ture, which is referred to as the chemo-
kine fold. Hence, chemokines are defined
through their function as chemoattractans
with a common secondary and tertiary
structure.
[1]
The spacing of the first two
cysteines has been used as a lead for sys-
tematic nomenclature: in the CC group the
cysteines are adjacent, in the CXC group
they are separated by any amino acid while
CX
3
C ligand 1 (CX
3
CL1) contains three
separating amino acids.
[2,3]
The chemo-
kines XCL1 and XCL2 fall somewhat out
of the rule as they possess only one disul-
fide bridge, but share the chemokine fold.
The primary sequences of chemokines are
highly divergent, but almost all give rise
to a marked alkaline isoelectric point. In
fact this property has been used to isolate
chemokines from biological material (see
below). For the receptors, a nomenclature
was introduced based on the structural
features of the CXC, CC and CX
3
C che-
mokines, corresponding to CXC recep-
tors (CXCR), CC receptors (CCR) and the
CX
3
C receptor (CX
3
CR1), respectively.
All chemokines possess a flexible (un-
folded) N-terminus, preceding the first
cysteine followed by a rigid loop that ends
in three antiparallel β-strands (Fig. 1).
The C-terminus is helical and at its end
is also unfolded.Thedisulfide bridges [1-3]
and [2-4] connect the N-terminus of the
rigid loop with the β-strands. Functionally
relevant domains of chemokines are the
rigid loop, the N-terminus, and glycos-
aminoglycan (GAG) binding sites located
within the β-strands or in the C-terminus.
[4]
The rigid loop and the N-terminus are im-
portant for receptor binding and activation.
In the two-step model the chemokine first
binds with its rigid loop to the N-terminus
of a cognate receptor followed by the in-
sertion of its N-terminus into the activation
pocket of the receptor (Fig. 2).
[5]
Instead,
the GAG binding sites are in opposition to
the receptor-interacting domains enabling
presentation of the chemokine by pro-
teoglycans in an active conformation.
[6]
Indeed retention of chemokines on cell
surfaces or matrices is critical for the for-
mation of chemotactic gradients required
for directional cell migration.
[7,8]
The
N-terminus of the chemokine is most criti-
cal for receptor activation and substitution
of single amino acids or truncations can
lead to a total loss of activity or changes in
receptor specificity.
[9]
The notion is consis-
tent with the N-terminus falling deep into
the binding pocked formed by the trans-
membrane spanning helices of the GPCRs
and thereby inducing receptor conforma-
tional changes.
[5]
At physiological concentrations che-
mokines can oligomerize, a process that is
often assisted by sulfated sugars, such as
heparan sulfate.
[10,11]
However, monomeric
chemokines are fully active and may be
the major active entity in vivo.
[12]
In fact,
in some cases it was shown that mono-
meric and dimeric forms can induce dif-
ferent responses on the same receptor.
[13]
Moreover, in addition to homomers, che-
Fig. 1. Chemokine fold and structural features.
Monomeric human CXCL12 [22­93] X­ray
structure (PDBe Monomer_3GV).
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mation. Removal of guanidine by dialy-
sis in most cases causes the precipitation
of the crude material, but is a convenient
method for its isolation. Pellets are then
solubilized in a small volume of 6M gua-
nidine under strong reducing conditions
at high protein concentrations (5–10 mg/
ml). Due to their basic isoelectric points
unfolded chemokines are soluble at low
pH. Therefore, simple buffer exchange on
a desalting column equilibrated at pH 3
allows removal of the guanidine and the
reducing agent. Subsequent rapid dilution
into a redox-balanced buffer at physiologi-
cal pH, which favors disulfide bridge for-
mation in the presence of low molecular
weight chaperones, e.g. arginine, permits
efficient folding of chemokines. The dilut-
ed chemokines can be recovered by cation
chromatography or by reverse phase chro-
matography on neutral, pH resistant matri-
ces, such as POROS
®
R2 (Thermo Fisher
Scientific).
[25]
A critical step for the preparation of re-
combinant chemokines is the formation of
a correct N-terminus. Natural chemokines
are translated from their genes with a lead-
er sequence at the N-terminus, which is re-
quired for secretion and is cleaved off after
membrane translocation. This natural trun-
cation gives no preference for amino acids
at the N-terminus, whereas bacterial ex-
pressed chemokines start with a formylat-
ed methionine, which can significantly al-
ter receptor activation. The starting amino
acid of recombinantly produced chemo-
kines can be enzymatically removed after
purification with methionine aminopepti-
dases. Alternatively, if an affinity tag for
purification was added at the N-terminus,
insertion of a consensus sequence for pro-
teolytic cleavage allows the removal of this
part. A convenient protease for cleavage
is enterokinase, because the enzyme cuts
right after its specific consensus sequence
leaving no undesired amino acids at the
N-terminus of the chemokine.
[25,28]
Mature
chemokines can easily be separated from
uncleaved material or from the clipped
N-terminus by reversed-phase HPLC.
Alternatively, fusing an N-terminal
poly-histidine-SUMO (small ubiquitin-
related modifier) double tag to the chemo-
kine entails two advantages for generating
functional chemokines. First, the addition
of a SUMO-tag renders the recombinant
chemokine-fusion protein soluble and pre-
vents its accumulation in inclusion bodies.
The soluble poly-histidine-tagged-chemo-
kine-fusion protein can be easily purified
on a classical IMAC. Second, the poly-his-
tidine-SUMO tag can be cleaved off with
an impeccable specificity and efficiency
using the SUMO protease 1 (Ulp1) liber-
ating the native chemokine with its correct
mature N-terminus.
[29,30]
If Ulp1 is used as
poly-histidine-tagged version, both Ulp1,
rification. In those days the human genome
was not sequenced and therefore classical
amino acid sequencing by Edman degrada-
tion was performed to reveal the primary
sequence. It turned out that the sequence
was identical to that of a predicted secreted
protein deduced from cDNA, which was
obtained by reverse transcription ofmRNA
from mitogen-stimulated leukocytes.
However, the hypothetical product was not
characterized.
[23]
The laboratory in Bern together with
the Sandoz (later Novartis) Research
Institute in Vienna went on and synthe-
sized the gene of mature CXCL8 through
hybridization of six overlapping synthetic
oligonucleotides. The artificial gene was
inserted into a plasmid and transduced
into E. coli for protein production.
[24]
Chemokines, when expressed in bacteria,
are usually not soluble, but form densely
packed amorphous inclusion bodies.
[25,26]
Apossible explanation for the formation of
inclusion bodies is that many chemokines
are bactericidal either in their full-length
conformation or as cleavage products and
bacteria may store the toxic material in an
inactive conformation.
[27]
Chemokines can easily be extracted
from inclusion bodies and folded into
their functional conformations. The amor-
phous insoluble structures are a conve-
nient source for 80–90% pure chemokine.
Inclusion bodies are isolated by differen-
tial centrifugation, rigorously washed with
mild chaotropic reagents, e.g. 2Murea, and
subsequently solubilized in 6M guanidine
HCl under strong reducing conditions to
break disulfide bridges. For convenience,
recombinant chemokines are often tagged
with histidines so that they can be easily
isolated on immobilized metal ion affinity
columns (IMAC). This chromatography
step usually yields >95% pure chemokines
which are in a linear and unfolded confor-
mokines can also oligomerize with other
chemokines and trigger responses, which
are often synergistic, i.e.more pronounced
than elicited by the individual chemokines
alone.
[14–16]
The physiological relevance of
the synergism is given at sites of inflam-
mation where multiple chemokines are
produced concomitantly. Finally, chemo-
kines can interact with heterologous pro-
teins, e.g. CXCL12 binds the alarmin high
mobility group box 1 (HMGB1), which is
secreted by immune cells at sites of inflam-
mation, leading to markedly altered recep-
tor responses.
[17]
Identification of CXCL8 and its First
Recombinant Expression
Neutrophils are the most abundant
white blood cells in the circulation and
constitute the front line defense of the
innate immune system of vertebrates. In
the late 1980s almost concomitantly four
laboratories, three in Europe and one in
the USA, reported the sequence of a mono-
cyte-derived neutrophil activating peptide.
[18]
In Switzerland the laboratory of Marco
Baggiolini at the Theodor Kocher Institute
of the University of Bern isolated CXCL8,
whichhadbeenoriginallycalledNeutrophil
Activating Factor (NAF), and was later
renamed to NAP-1 and IL-8. In all labo-
ratories CXCL8 was purified from super-
natants of stimulated monocytes through
classical biochemical protein purification
procedures including ammonium sulfate
precipitation, different steps of column
chromatography, such as size exclusion,
ion-exchange and reverse-phase high pres-
sure liquid chromatography (HPLC).
[19–22]
The protocols used chemotaxis and en-
zyme release from intracellular granules
of neutrophils as bio-assays to follow the
activity in the different fractions during pu-
Fig. 2. Two­step chemokine receptor binding model. Chemokines (in yellow) first dock to the
N­terminus of the heptahelical receptor via their rigid loop (RL). Subsequently, the N­terminus of
the chemokine falls into the binding pocket embedded in the transmembrane helices leading to
receptor conformational changes (indicated in light blue) and receptor activation. N­termini (N),
C­termini (C). Figure adapted from Crump et al.
[5]
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germinal center reaction and drives hom-
ing of long-lived plasma cells to niches in
the bone marrow. The CXCL12/CXCR4
couple is also necessary for myelopoiesis
in the bone marrow. CXCL12, although
considered mostly as a homeostatic che-
mokine, can be involved in inflammatory
responses.
[1]
Another monogamous couple is con-
stituted by the CXCL13/CXCR5 pair. The
key function of the pair is the regulation
of leukocyte trafficking within second-
ary lymphoid organs under healthy and
inflammatory conditions. Thus CXCL13
guides CXCR5
+
leukocytes, such as fol-
licular helper T cells and B cells, to fol-
licles. Furthermore, CXCL13 together
with CXCL12 are the main chemokines
for the segregation of the light and dark
zone of germinal centers of secondary
lymph nodes, respectively.
[1]
In the germi-
nal centers, B cells undergo affinity matu-
ration and receptor class switch, a critical
step in generating high affinity antibodies.
In the dark zone, B cells proliferate, while
in the light zone selection of high affinity
antigen-specific B cells occurs.
Seven of the inflammatory CXC che-
mokines contain the ELR motif just in
front of the first cysteine. All chemokines
containing the ELR motif bind with simi-
lar affinity to CXCR2, the second recep-
tor initially identified to bind CXCL8,
while CXCR1 shows high affinity only for
CXCL8.
[1,2]
Interestingly, CXCL8, which
binds to CXCR1 and CXCR2, induces
stronger responses through CXCR1. The
receptors are expressed on neutrophils and
mediate the recruitment of front line im-
mune cells to sites of inflammation.
[41]
Of the CC group the inflammatory che-
mokine receptors, CCR1, CCR2, CCR2
and CCR5 are most important for leuko-
cyte recruitment during inflammation.
With partially overlapping specificity, they
share multiple CC chemokines as agonists.
Locally produced cognate chemokines re-
cruit lymphocytes and myelocytes to sites
of infection. By contrast, expression of
CCR4 is mainly restricted to T cells and
appears to be involved in skin homing of
the T lymphocytes. CCR4 binds two che-
mokines namely CCL17 and CCL22.
[1]
Next to their profound role in orches-
trating leukocyte trafficking in homeosta-
sis and inflammation, some chemokines
are critical for development and neoplas-
tic pathologies. A particular role is given
for CXCL12, because its genetic ablation
in mice leads to their perinatal death with
pronounced defects in central nervous
system development, heart function, B
cell lymphopoiesis and vascularization. In
addition, CXCR4, the sole functional re-
ceptor for CXCL12, is expressed on ma-
ny cancer cells and often responsible for
their metastatic behavior, such as homing
Chemokine Function
Chemokines are best known for their
regulation of leukocyte trafficking.
[34,35]
Leukocyte migration is required for im-
mune homoeostasis, surveillance and
responses to infiltrating pathogens.
Consequently, chemokines were function-
ally subdivided into two groups; on one
side there are those that primarily govern
homeostatic immune cell trafficking, but
can eventually become upregulated under
pathological conditions. On the other side
are chemokines that are mainly induced
and expressed under inflammatory condi-
tions, often called ‘inflammatory’ chemo-
kines.
[36]
The receptors of chemokines phyloge-
netically map to a group of GPCRs within
the gamma subfamily of rhodopsin-like
receptors that share the ability to mediate
cell migration.
[37]
Chemokine receptors
in general couple to heterotrimeric Gi-
proteins, therefore most responses can be
fully inhibited by treatment of cells with
Bordetella pertussis toxin. Today, a total
of 19 receptors have been identified: 7
CXCRs, (CXCR1-6 and CXCR8), which
is also known as GPR35, 10 CCRs (CCR1-
10), CX
3
CR1 and CKR1.
[1]
Compared
with the about 50 chemokines it becomes
evident that the 19 receptors usually bind
more than one chemokine, however, sev-
eral chemokines can also bind to multiple
receptors. The resulting promiscuity of the
chemokine system has important conse-
quences for immune responses, since a giv-
en receptor may induce different responses
depending on the chemokine that triggers
its activation. For example it was reported
that CXCR3 when stimulated with its high
affinity ligand CXCL11 skews T cells to-
wards a Th2 phenotype, whereas CXCL10,
which binds with lower affinity to the same
receptor, induces Th1 differentiation.
[38]
Th1 and Th2 T cells are known to mediate
distinct immune responses.
[39]
CCR7 binds two chemokines, CCL19
and CCL21, and is a key regulator for the
homing of leukocytes, such as dendritic
cells, B and T cells, to secondary lymphoid
organs. Although CCL19 and CCL21 both
bind to CCR7, the two ligands can induce
distinct signaling pathways. The binding
of CCL19 to CCR7 leads to receptor in-
ternalization, while CCL21 promotes cell
adhesion facilitated by tightly binding to
GAGs through its extended C-terminus
building haptotactic gradients for cell mi-
gration.
[40]
The chemokine primarily responsive
for the homing and maintenance of hema-
topoietic stem cells in the bone marrow is
CXCL12, the sole ligand of CXCR4. The
CXCL12/CXCR4 axis is critical for B cell
development and is required during lym-
phopoiesis, during differentiation in the
as well as the poly-histidine-SUMO tag
can simply be removed by re-running the
protein over an IMAC.
[31]
Chemical Synthesis
An alternative method to generate che-
mokines is full chemical solid-phase syn-
thesis. Due to the relatively short amino
acid sequence and the favorable folding
properties, chemical synthesis is an elegant
and efficient method, however, this method
requires specialized laboratory equipment
andchemical knowhow,whicharenot com-
monly found in life science-dedicated lab-
oratories. In the early 90s Ian Clark-Lewis
inVancouver was amongst the first starting
to synthesize chemokines.
[32]
His protocol
is based on automated solid-phase synthe-
sis of chemokines, which are then cleaved
off from the resin, chemically deprotected
and precipitated from organic solvents.
Guanidine and strong reducing conditions
were used to solubilize the crude material
in aqueous buffers at pH 3.After separation
on a reversed-phase column, chemokines
were subjected to folding. Correctly folded
proteins, which possess typically a more
hydrophilic surface bind markedly less
well to reverse phase, can easily be sepa-
rated from unfolded material. Chemical
synthesis provides several advantages.
Only one product with a defined sequence
is obtained and no cleavage of amino acids
from the N-terminus is required. Chemical
synthesis also allows the protein sequence
to be manipulated and non-natural amino
acids to be introduced. Because random
chemical labeling interferes with receptor
binding, site-specific modifications are of-
ten required for biological studies, includ-
ing the determination of receptor affin-
ity and of receptor surface expression (in
the absence of available receptor-specific
antibodies). Fluorophore-labeled or bioti-
nylated amino acids are often introduced
near the C-terminus and were shown not
to modify receptor interactions. Chemical
synthesis was also used for a systematic
truncation and modification of the amino-
terminal sequence preceding the first cys-
teine of CXCL8 to unveil the importance
of this domain for receptor binding and
activation. The extensive studies of struc-
ture–function relations included a large
number of synthetic analogs with single
amino acid substitutions and showed that,
with the exception of the cysteines and
the glutamic acid-leucine-arginine motif
(ELR motif), no other residue appeared to
be required for functional CXCL8 receptor
interaction.
[33]
life sciences in switzerland CHIMIA 2016, 70, No. 12 859
[24] I. Lindley, H. Aschauer, J. M. Seifert, C. Lam,
W. Brunowsky, E. Kownatzki, M. Thelen, P.
Peveri, B. Dewald, V. von Tscharner, A. Walz,
M. Baggiolini, Proc. Natl. Acad. Sci. USA 1988,
85, 9199.
[25] B. Moepps, M. Thelen, Methods Enzymol.
2016, 570, 87.
[26] A. E. Proudfoot, F. Borlat, Methods Mol. Biol.
2000, 138, 75.
[27] M. Wolf, B. Moser, Front. Immunol. 2012, 3,
213.
[28] O.O.Yang, S. L. Swanberg, Z. Lu,M.Dziejman,
J. McCoy, A. D. Luster, B. D. Walker, S. H.
Herrmann, J. Virol. 1999, 73, 4582.
[29] Q. Lu, M. C. Burns, P. J. McDevitt, T. L.
Graham,A. J. Sukman, J.A. Fornwald, X. Tang,
K. T. Gallagher, G. E. Hunsberger, J. J. Foley,
D. B. Schmidt, J. J. Kerrigan, T. S. Lewis, R.
S. Ames, K. O. Johanson, Protein Expr. Purif.
2009, 65, 251.
[30] C. T. Veldkamp, C. A. Koplinski, D. R. Jensen,
F. C. Peterson, K. M. Smits, B. L. Smith, S.
K. Johnson, C. Lettieri, W. G. Buchholz, J. C.
Solheim, B. F. Volkman, Methods Enzymol.
2016, 570, 539.
[31] M. A. Hauser, I. Kindinger, J. M. Laufer, A. K.
Spate, D. Bucher, S. L. Vanes,W.A. Krueger, V.
Wittmann, D. F. Legler, J. Leukoc. Biol. 2016,
99, 993.
[32] I. Clark-Lewis, Methods Mol. Biol. 2000, 138,
47.
[33] I. Clark-Lewis, B. Dewald, M. Loetscher, B.
Moser, M. Baggiolini, J. Biol. Chem. 1994, 269,
16075.
[34] M. Baggiolini, Nature 1998, 392, 565.
[35] M. Thelen, J. V. Stein, Nat. Immunol. 2008, 9,
953.
[36] M. Thelen, M Uguccioni, ‘Function of
Chemokines and Their Receptors in Immunity’,
in ‘Encyclopedia of Immunobiology’, Ed. M. J.
H. Ratcliffe, 2016.
[37] R. Fredriksson, M. C. Lagerstrom, L. G.
Lundin, H. B. Schioth, Mol. Pharmacol. 2003,
63, 1256.
[38] Y. Zohar, G. Wildbaum, R. Novak, A. L.
Salzman, M. Thelen, R. Alon, Y. Barsheshet,
C. L. Karp, N. Karin, J. Clin. Invest. 2014, 24,
2009.
[39] N. Karin, G. Wildbaum, M. Thelen, J. Leukoc.
Biol. 2016, 99, 857.
[40] M. A. Hauser, D. F. Legler, J. Leukoc. Biol.
2016, 99, 869.
[41] S. A. Jones, M. Wolf, S. Qin, C. R. Mackay, M.
Baggiolini, Proc. Natl. Acad. Sci. USA 1996,
93, 6682.
[6] Y. Monneau, F. Arenzana-Seisdedos, H. Lortat-
Jacob, J. Leukoc. Biol. 2016, 99, 935.
[7] M. H. Ulvmar, K. Werth, A. Braun, P. Kelay, E.
Hub, K. Eller, L. Chan, B. Lucas, I. Novitzky-
Basso, K. Nakamura, T. Rulicke, R. J. Nibbs, T.
Worbs, R. Forster, A. Rot, Nat. Immunol. 2014,
15, 623.
[8] M. Weber, R. Hauschild, J. Schwarz, C.
Moussion, V. de, I, D. F. Legler, S. A. Luther, T.
Bollenbach, M. Sixt, Science 2013, 339, 328.
[9] I. Clark-Lewis, C. Schumacher, M. Baggiolini,
B. Moser, J. Biol. Chem. 1991, 266, 23128.
[10] S. E. Crown,Y.Yu, M. D. Sweeney, J. A. Leary,
T. M. Handel, J. Biol. Chem. 2006, 281, 25438.
[11] T. M. Handel, Z. Johnson, D. H. Rodrigues, A.
C. Dos Santos, R. Cirillo, V. Muzio, S. Riva,
M. Mack, M. Deruaz, F. Borlat, P. A. Vitte, T.
N. Wells, M. M. Teixeira, A. E. Proudfoot, J.
Leukoc. Biol. 2008, 84, 1101.
[12] K. Rajarathnam, B. D. Sykes, C. M. Kay, B.
Dewald, T. Geiser, M. Baggiolini, I. Clark-
Lewis, Science 1994, 264, 90.
[13] L. J. Drury, J. J. Ziarek, S. Gravel, C. T.
Veldkamp, T. Takekoshi, S. T. Hwang, N.
Heveker, B. F. Volkman, M. B. Dwinell, Proc.
Natl. Acad. Sci. USA 2011, 108, 17655.
[14] K. Kuscher, G. Danelon, S. Paoletti, L. Stefano,
M. Schiraldi, V. Petkovic, M. Locati, B. O.
Gerber, M. Uguccioni, Eur. J. Immunol. 2009,
39, 1118.
[15] S. Paoletti, V. Petkovic, S. Sebastiani, M. G.
Danelon, M. Uguccioni, B. O. Gerber, Blood
2005, 105, 3405.
[16] A. E. Proudfoot, M. Uguccioni, Front. Immunol.
2016, 7, 183.
[17] M. Schiraldi, A. Raucci, L. M. Munoz, E.
Livoti, B. Celona, E.Venereau, T.Apuzzo, M. F.
De, M. Pedotti, A. Bachi, M. Thelen, L. Varani,
M. Mellado, A. Proudfoot, M. E. Bianchi, M.
Uguccioni, J. Exp. Med. 2012, 209, 551.
[18] M. Baggiolini, Front. Immunol. 2015, 6, 285.
[19] A. Walz, P. Peveri, H. Aschauer, M. Baggiolini,
Biochem. Biophys. Res. Commun. 1987, 149,
755.
[20] T. Yoshimura, K. Matsushima, S. Tanaka, E. A.
Robinson, E. Appella, J. J. Oppenheim, E. J.
Leonard, Proc. Natl. Acad. Sci. USA 1987, 84,
9233.
[21] H. Gregory, J. Young, J. M. Schroder, U.
Mrowietz, E. Christophers, Biochem. Biophys.
Res. Commun. 1988, 151, 883.
[22] J.Van Damme, J. van Beeumen, G. Opdenakker,
A. Billiau, J. Exp. Med. 1988, 167, 1364.
[23] J. Schmid, C. Weissmann, J. Immunol. 1987,
139, 250.
to bone marrow and lymphoid organs, re-
spectively.
[1]
In conclusion, the production – and
the chemical synthesis in particular – of
natively folded and pure chemokines, is
instrumental for a variety of basic, trans-
lational, as well as clinical research pro-
grams. Researchers in Switzerland have
taken a pioneering role in chemokine re-
search which includes the co-discovery of
the first chemokine
[18]
and substantially
contributed to the understanding of che-
mokine functions in biomedicine. The
field would greatly profit by integrating
synthetic chemistry (again) in chemokine
research programs.
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